RG6189
/ Roche
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
July 19, 2024
Fibroblast activation protein (FAP)-CD40 (RO7300490) mediates intratumoral DC maturation and modulation of the tumor microenvironment
(ESMO 2024)
- P1, P1/2, P1b, P1b/2a, P2 | "In summary, targeting CD40 agonism to the tumour achieved a strong and sustained target engagement and tumour tissue immunomodulation with a favourable safety profile at all tested doses, supporting further studies in combination with other anti-cancer agents in earlier lines of treatment."
Biomarker • IO biomarker • Tumor microenvironment • Oncology • Solid Tumor • CD40 • FAP • LAMP3
February 05, 2024
A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=80 | Completed | Sponsor: Hoffmann-La Roche | Recruiting ➔ Completed
Trial completion • Oncology • Solid Tumor
September 27, 2023
A Phase I study of a tumor-targeted, fibroblast activation protein (FAP)-CD40 agonist (RO7300490) in patients with advanced solid tumors
(SITC 2023)
- P1 | "In summary, targeting CD40 agonism to the tumor has led to a favorable safety profile at doses with strong and sustained target engagement, and supports further studies in combination with other anti-cancer therapies. The patients and their families The study investigators and members of the clinical study teams."
Clinical • Metastases • P1 data • Oncology • Solid Tumor • CD40 • FAP
1 to 3
Of
3
Go to page
1